Medicare expands cancer prevention coverage for high-risk families
S. 2760 — Reducing Hereditary Cancer Act of 2025 · Filed by Lisa Murkowski (R-AK) · 1 cosponsor · Introduced Sep 10, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill expands Medicare coverage for genetic testing to identify hereditary cancer risk, preventive surgeries for high-risk individuals, and enhanced cancer screening (mammography, colonoscopy, PSA testing, etc.) for people with hereditary cancer mutations. It requires Medicare to follow evidence-based clinical guidelines from oncology organizations and cover these services starting immediately upon enactment.
Why we flagged it
The bill's core function is to mandate Medicare coverage of genetic testing, preventive surgeries, and enhanced screening for individuals at hereditary cancer risk, following evidence-based clinical guidelines. This is straightforward public-health legislation with no hidden mechanism.
What the text implies
- Increased demand for genetic counseling and oncology services may strain provider capacity, particularly in rural areas with limited genetic specialists.
- Medicare Administrative Contractors gain discretionary authority to select among conflicting clinical guidelines ('least restrictive'), creating potential for inconsistent coverage decisions across regions.
The full analysis lists 4 implications of this text.
Who stands to gain
genetic testing companies; oncology practices and surgical centers; diagnostic imaging providers (mammography, MRI)